nafronyl has been researched along with Labyrinth Diseases in 2 studies
Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
Labyrinth Diseases: Pathological processes of the inner ear (LABYRINTH) which contains the essential apparatus of hearing (COCHLEA) and balance (SEMICIRCULAR CANALS).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hahn, A | 1 |
| Pilgramm, M | 1 |
| Lamm, H | 1 |
| Schumann, K | 1 |
2 other studies available for nafronyl and Labyrinth Diseases
| Article | Year |
|---|---|
[Dusodril in the ambulatory care of inner ear disorders].
Topics: Adolescent; Adult; Aged; Female; Furans; Humans; Labyrinth Diseases; Male; Middle Aged; Nafronyl | 1989 |
[Hyperbaric oxygen therapy in sudden deafness].
Topics: Audiometry, Pure-Tone; Auditory Threshold; Combined Modality Therapy; Female; Hearing Loss, Sudden; | 1985 |